argenx SE
efgartigimod
myositis
Resolved
34days ago
Phase 2 readout · Jun 3, 2026
What's at stake
Phase 2 trial results for efgartigimod in myositis are due Jun 3, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“Long-Term Efficacy and Safety of Efgartigimod in Sjogren’s Disease: Findings from the RHO+ Open-Label Extension Study”